Targeted alpha-particle therapy

AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer

Retrieved on: 
Tuesday, November 7, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Alpha particle, Prostate, Prostate cancer, MD, University of California, San Francisco, University, Peter MacCallum Cancer Centre, University of California, Los Angeles, Cancer, Targeted alpha-particle therapy, PSMA, Patient, Letter, Medical imaging, Pharmaceutical industry

“The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, and our patients,” said Andrew Adamovich, CEO of AdvanCell.

Key Points: 
  • “The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, and our patients,” said Andrew Adamovich, CEO of AdvanCell.
  • “We believe that 212Pb is the ideal radioisotope to realise the full therapeutic power of Targeted Alpha Therapy.
  • “We are excited to be moving this 212Pb-based therapy forward in the TheraPb clinical study.”
    Developed the world’s first 212Pb-based Targeted Alpha Therapy to enter clinical trials in metastatic prostate cancer.
  • Developed a proprietary target discovery and ligand development program encompassing a robust pipeline of Targeted Alpha Therapies to treat cancer.

MIT Validates Serva Energy's Novel Production Method of Life-saving Actinium-225 Isotope

Retrieved on: 
Wednesday, November 1, 2023
Actinium, MIT, Nuclear medicine, Radiology, Thought, Clinical professor, Radiopharmaceutical, Isotopes of radium, MIT Nuclear Research Reactor, Targeted alpha-particle therapy, Mayo Clinic, Uranium mining, Radiochemistry, Serva

TEMPE, Ariz., Nov. 1, 2023 /PRNewswire/ -- Serva Energy 's sample measurement of the rare cancer-killing medical isotope Actinium-225 (Ac-225) has been validated by the MIT Nuclear Research Laboratory.

Key Points: 
  • TEMPE, Ariz., Nov. 1, 2023 /PRNewswire/ -- Serva Energy 's sample measurement of the rare cancer-killing medical isotope Actinium-225 (Ac-225) has been validated by the MIT Nuclear Research Laboratory.
  • It's the latest milestone in Serva's development of commercial quantities of Ac-225 needed for next-generation Targeted Alpha Therapies.
  • In June, Serva Energy announced a novel reactor-based method to produce significantly greater amounts of medical-grade Ac-225—marking the first time a commercial entity has used a conventional nuclear reactor to create the ultra-rare isotope.
  • "Plans to quickly optimize and scale up any production of this potentially critical medical isotope will be crucial in establishing a reliable supply of Ac-225."

Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Monday, August 28, 2023
Neuroblastoma, Abstract, MBBS, Metastasis, EANM, Glomus tumor, Targeted molecular therapy for neuroblastoma, MBA, DNB, Nuclear medicine, PET-CT, Perspective, European Association of Nuclear Medicine, CATX, MD, Patient, Molina Healthcare, FMRI, Cancer, Therapy, NYSE, Targeted alpha-particle therapy, Pharmaceutical industry, Safety, IOWA

RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) --  – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 212Pb-VMT-α-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM).

Key Points: 
  • RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) --  – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 212Pb-VMT-α-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM).
  • “Our team at Perspective Therapeutics continues to work diligently to advance much needed targeted alpha therapy using 212Pb,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics.
  • “We are particularly excited about the early clinical results from 212Pb-VMT-α-NET in patients suffering from different types of difficult-to-treat neuroendocrine tumors.
  • The data showed that fractionated doses of [212Pb]VMT-α-NET provided greater benefit than single dose administration of [212Pb]VMT-α-NET.

Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy

Retrieved on: 
Thursday, May 11, 2023
SEQUOIA, DARPin, Antigen, Society, AACR, Nephrotoxicity, ASH, Therapy, DME, CD70, CD3, TAA, Neoplasm, TAT, Diabetic retinopathy, NAMD, American Society of Clinical Oncology, LR, SITC, American Association for Cancer Research, Immunotherapy, RDT, Toxicity, Research, FAP, Cell, Stem cell, ASCO, Service provider, Society for Immunotherapy of Cancer, Radiation, DLL3, International Symposium on Symbolic and Algebraic Computation, Novartis, Patient, CD123, Molecular Partners, CD33, CD40, Kidney, Depreciation, Ranibizumab, R, Letter, CHF, Tumor microenvironment, Targeted alpha-particle therapy, Pharmaceutical industry, Vaccine, CONCORD, AML

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its interim management statement for the quarter ending March 31, 2023.

Key Points: 
  • 53 LR:
    Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its interim management statement for the quarter ending March 31, 2023.
  • “This quarter we made advances across our portfolio, including two clinical-stage oncology programs, MP0317 for solid tumors and MP0533 for AML.
  • We anticipate analyzing these data and working with potential partners to determine the best combinations and indications for the program.
  • The Company continues to evaluate potential business opportunities for abicipar outside of internal development at Molecular Partners.

Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy

Retrieved on: 
Wednesday, March 8, 2023
Radiology, Professional Services, Pharmaceutical, Oncology, Start-Up, Medical Devices, University, Other Manufacturing, Education, Clinical Trials, Manufacturing, Health, Acceleration, Nuclear medicine, Nature, Japan Science and Technology Agency, Ris, Kita, Radiopharmaceutical, Targeted alpha-particle therapy, TAT, Research, Thyroid cancer, Technology Agency of the Czech Republic, Bismuth, OPERA, RI, SHI, Drug discovery, JST, Fukushima Medical University, Multimedia, Halogen, AF, Isotope, Osaka University, Mission, Head, Pharmaceutical industry, Atomic, Astatine

Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in Alpha Fusion Inc. (“AF”) (Head Office: Kita-ku, Osaka, Chief Executive Officer: Sunao Fujioka), a developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy (“TAT”).

Key Points: 
  • Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in Alpha Fusion Inc. (“AF”) (Head Office: Kita-ku, Osaka, Chief Executive Officer: Sunao Fujioka), a developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy (“TAT”).
  • View the full release here: https://www.businesswire.com/news/home/20230308005372/en/
    Image Diagram of TAT (Graphic: Business Wire)
    AF will aim at establishing their pipeline (*1).
  • Development of their radiopharmaceuticals is expected to be progressed by this funding and will lead more needs of Astatine-211.
  • Astatine-211 (211At, Atomic number 85, Half life time 7.2H) is an element belonging to halogens and has the property of emitting alpha particle.

Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform

Retrieved on: 
Tuesday, February 28, 2023
Radioactive decay, Safety, Molecular Partners, Senior, Research, TAT, DARPin, TAT12, Doctor of Philosophy, Neoplasm, Kidney, Therapy, Targeted alpha-particle therapy, DLL3, Novartis, International Symposium on Endovascular Therapy, Poster, Pharmaceutical industry, CONCORD

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the presentation of new preclinical data from the company’s Radio DARPin Therapy Platform at the 12th International Symposium on Targeted Alpha Therapy (TAT 12) in Cape Town, South Africa on February 28, 2023. The platform represents a unique and innovative delivery system for radioactive payloads to solid tumors, an approach with proven potential but with technological limitations that DARPins may address.

Key Points: 
  • 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the presentation of new preclinical data from the company’s Radio DARPin Therapy Platform at the 12th International Symposium on Targeted Alpha Therapy (TAT 12) in Cape Town, South Africa on February 28, 2023.
  • The platform represents a unique and innovative delivery system for radioactive payloads to solid tumors, an approach with proven potential but with technological limitations that DARPins may address.
  • These results will be presented at TAT12 in a poster, the details of which can be found below.
  • The poster will be made available on Molecular Partners website, after the presentation.

Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine

Retrieved on: 
Monday, February 6, 2023
Radiology, Biotechnology, Pharmaceutical, Oncology, General Health, Health, Health Technology, Other Health, Cancer, NYSE, Patient, Viewpoint, Radiation, Peptide, Growth, ISR, Chairperson, Radiopharmaceutical, Targeted alpha-particle therapy, Pharmaceutical industry, Medical imaging

Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular Targeting, Inc.

Key Points: 
  • Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular Targeting, Inc.
  • Viewpoint Molecular Targeting CEO Thijs Spoor has been named Chief Executive Officer and outgoing Isoray CEO Lori Woods assumed the role of Chairperson of the Board of Directors of the combined companies.
  • Outgoing Isoray CEO Lori Woods said, “This merger represents an important milestone for Isoray.
  • The merger with Viewpoint Molecular Targeting demonstrates our commitment to build on our shared belief of treating cancers from the inside out while providing personalized targeted treatment options for cancer patients.

RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH

Retrieved on: 
Tuesday, November 15, 2022
Diagnosis, PET, Low-density lipoprotein receptor-related protein 8, PDAC, Cancer, Connective tissue, Brain, PET/CT, Patient, Pancreatic cancer, Neoplasm, LDLR, Glioblastoma, Baantjer, de film: De Cock en de wraak zonder einde, CGMP, US, Targeted alpha-particle therapy, GBM, Pancreas, Radiation, CSO, Aix-Marseille University, TAT, Radiopharmaceutical, Investigational New Drug, Quality of life, CNRS, Clinical trial, Traffic barrier, US FDA, Safety, Drug development, Medical imaging

PDAC is one of the most chemo-resistant and radio-resistant types of cancers due to the dense pancreatic connective tissue and the diversity of genetic mutations.

Key Points: 
  • PDAC is one of the most chemo-resistant and radio-resistant types of cancers due to the dense pancreatic connective tissue and the diversity of genetic mutations.
  • Our current therapeutic approaches for these cancers are invasive and fail meaningful results while adversely effects on the quality of life of our patients.
  • RadioMedix is serving as a Sponsor and manufacturer of the clinical doses of 68Ga-RMX-VH., said Dr. Izabela Tworowska, CSO of RadioMedix.
  • In addressing other unmet needs in oncology, RadioMedix is developing theranostic agents to treat brain tumors, and pancreatic ductal adenocarcinoma (PDAC).

AdvanCell Closes A$18M Series B Funding Led by Morningside

Retrieved on: 
Wednesday, August 24, 2022
Research, Men, Biotechnology, Radiology, General Health, Pharmaceutical, Consumer, Health, Science, Oncology, Radiochemistry, Hamstringing, Technology, CEO, Research, Federal, Alpha particle, Director, Board, Chair, Course, Isotope, Social responsibility, Targeted alpha-particle therapy, Australian Nuclear Science and Technology Organisation, Company, Research and Development Tax Incentive, Element, Coronavirus Scientific Advisory Board (Turkey), ANSTO, Founder, Alpha, Growth, Adoption, Patient, Pharmaceutical industry, Management, Medical imaging, Cancer

AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.

Key Points: 
  • AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.
  • AdvanCell believes this precise and powerful treatment will rapidly become a leading pillar of cancer treatment, providing treatments for diseases for which there are currently no effective options.
  • AdvanCell has a world-class team and is honoured to be advised by an outstanding Board of Directors and Scientific Advisory Board.
  • For more information visit www.advancell.com.au
    Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm.

US FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL

Retrieved on: 
Sunday, July 24, 2022
Signal transduction, Death, Environment, United Kingdom, Injection, Virbac, Journal of Veterinary Internal Medicine, Human, Sarcoma, PKC, Extremities, Safety, Targeted alpha-particle therapy, Cancer, Recurrence, Tigilanol tiglate, DOI, Patient, Neoplasm, Pharmacokinetics, Animal, EBioMedicine, Wound healing, Pharmaceutical industry, Medical imaging, Vaccine

Evaluate the degree of tumour ablation in tumours and or tumour segments treated with one or more injections of tigilanol tiglate.

Key Points: 
  • Evaluate the degree of tumour ablation in tumours and or tumour segments treated with one or more injections of tigilanol tiglate.
  • QBiotics' lead oncology product, tigilanol tiglate, is a small molecule targeting a range of solid tumours across multiple species.
  • Tigilanol tiglate has a multimodal action that involves injected tumour responses as well as systemic responses in non-injected tumours.
  • Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate.